Current Atherosclerosis Reports

Papers
(The H4-Index of Current Atherosclerosis Reports is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Revascularization Options for Left Main Disease: What Clinicians Need to Know169
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions154
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?125
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management122
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes117
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis98
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?73
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease70
The Role of the PI3K/Akt/mTOR Pathway in Atherosclerosis: Mechanisms, Therapeutic Potential, and Emerging Targeted Treatments68
The Effects of FABP4 on Cardiovascular Disease in the Aging Population61
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators60
Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis52
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice46
Salutary Effects of Nutritional Ketosis for the Diseased Human Heart45
Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event44
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review43
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease41
Inflammation in the Peri-ACS Period: Ready for Prime Time?39
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?39
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?38
Percutaneous Coronary Interventions in Women38
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease38
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?36
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention36
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women36
Lipoprotein(a): from Causality to Treatment35
The Emerging Specialty of Cardio-Rheumatology34
The Role of Sleep in Cardiovascular Disease33
Myeloid Cells in Abdominal Aortic Aneurysm33
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger32
Low LDL-C: Is It all Good News?32
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?32
Importance of Nutrition Security to CVD Prevention Efforts in the USA32
0.09775185585022